- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
Dr Kashyap Patel: Biosimilars and Value
Kashyap Patel, MD, medical oncologist at Carolina Blood and Cancer Care, discusses the value that biosimilars bring to the health system.
Transcript:
What value do biosimilars bring to our healthcare system?
The first thing we have to do is to educate providers, payers, and patients, about what biosimilars are and what the benefits are. One clear benefit we see for the payer is the cost savings. To the patients, it’s their out-of-pocket costs; if the patient has to pay 20% out of pocket, for the cost of care, biosimilars will definitely reduce their out-of-pocket costs when they are used. For the providers, of course, if you’re in the alternate payment model space, and if you have an alternative that is equally effective and less expensive, it helps me to bring down my top price.
So in the European experience, you go back to Sweden and England, the health systems increased uptake and utilization of biosimilars, which indicates that when the price goes down, the access improves. This is very obviously starting the financial toxicity model. So biosimilars do have a place in improving access to drugs as well.
Switching From Avastin to Bevacizumab-bvzr in CRC, NSCLC Can Reduce Medicare Costs
May 10th 2025Monthly savings from fully converting Medicare patients with metastatic colorectal cancer (CRC) and non-squamous metastatic non-small cell lung cancer (NSCLC) from reference bevacizumab to bevacizumab-bvzr could fund 13,887 and 8,959 additional patient-months of treatment, respectively, according to a cost-effectiveness study.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Samsung Bioepis Report Signals Turning Point for US Biosimilars
May 1st 2025A wave of biosimilar approvals, aggressive pricing strategies, and a regulatory sea change are setting the stage for unprecedented momentum in the US biologics market, with 2025 already proving to be a landmark year in reshaping cost, access, and innovation across therapeutic areas.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Latest Biosimilar Deals Signal Growth Across Immunology, Oncology Markets
April 14th 2025During Q1 2025, pharmaceutical companies accelerated biosimilar expansion through strategic acquisitions and partnerships in hopes of boosting patient access to lower-cost treatments in immunology and oncology.
